guidanc new chapter begin
issu solid result adj ep top street consensu
look especi given recent complet express
script deal manag issu ep guidanc although
outlook hair street consensu manag clarifi
strand overhead cost larg come
manag note remain track long-term target
compani also project earn account full-year ep
due guidanc commentari lower ep estim
maintain estim price
target
recap integr medic incom driven mcr
opco/street off-set sg opco/
street meanwhil group l/other
flattish y-i new health-servic segment
day account
review guidanc ep guidanc
base integr medic incom
appear conserv though includ headwind individu
result meanwhil health-servic earn expect
inclus esrx accret synergi
ramp ci still expect synergi
cost caus temporari drag slight drag guidanc
vs expect due overhead cost
elimin variou initi along organ growth use
capac busi guidanc assum accret
exclud strand cost discuss
drug propos concern manag concern
recent hh drug propos look overhaul current rebat
structur among thing manag highlight compani
retain drug rebat receiv volum
alreadi reimburs structur pass rebat
continu project robust growth esrx deal believ stock
still reflect signific upsid result maintain outperform
rate would continu buyer
year price histori ci
provid health care relat
benefit us intern
compani offer insur self-
health vision plan well
disabl life insur product
analyst certif import disclosur see disclosur
integr includ express script goe
portfolio target strong growth market avoid
mani risk driven concentr aso
busi compani also strong track record growth
recent year tradit trade discount
peer although posit neg
express script deal believ highli accret deal
pay strong long-term return sharehold given compel
opportun cross-sel servic mention
equity-friendli capit structur result rate stock
guidanc issu updat
integr includ express script goe well
medicar busi growth margin acceler
signific uptick util
integr includ express script goe poorli
disabl life busi continu face volatil
exchang busi turn materi loss
price target base combin two methodolog dcf valuat base beta
termin growth rate wacc estim ebitda price-to-earnings target repres
ep estim conserv discount group current trade compani face
integr risk express script transact
includ healthcar reform federal/st regul chang cost trend intern busi risk
premium fee
healthcar premium
sell gener administr expens
premium fee
pharmaci servic cost elimin
total benefit expens
incom attribut non-controlling interest
dilut ep report
premium fee
sell gener administr expens
total benefit expens
